Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 132

Vor Biopharma forces through $177m IPO

The share price of the cellular oncology drug developer, which counts Novartis, Johnson & Johnson and PureTech Health as investors, has doubled since it floated.

Feb 9, 2021

Terns directs itself on to public markets

The Eli Lilly-backed liver disease drug developer floated at the top of its range to raise almost $128m, following $207m of venture funding.

Feb 9, 2021

Immunocore makes $258m impact in IPO

Eli Lilly and WuXi AppTec scored exits from the immunotherapy developer, which has seen its shares rocket 66% since it floated.

Feb 8, 2021

Bolt strikes public markets in $230m IPO

The Novo, Pfizer and Nan Fung-backed oncology therapy developer priced an upsized offering above its range and is now valued above $1bn.

Feb 8, 2021

Veracyte decides on $600m Decipher Biosciences purchase

Merck & Co and UnitedHealth Group are set to exit the urologic cancer diagnostics technology provider in an acquisition by Veracyte.

Feb 8, 2021

Sensei graduates to $133m IPO

The Cambrian Biopharma-backed cancer treatment developer floated above its range in an offering on the Nasdaq Global Market.

Feb 8, 2021

Tencent tops up Vision Medicals series C round

Gene-sequencing technology developer Vision Medicals has completed a $30.9m round led by Tencent that took its total funding to approximately $74m.

Feb 5, 2021

Corporate venturing deal net: 1-5 February 2021

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Feb 5, 2021

23andMe links to Virgin in $3.5bn reverse merger

The corporate-backed genetic testing service is joining forces with an NYSE-listed special purpose acquisition company sponsored by Virgin Group.

Feb 5, 2021

Sana Bio plants itself on public markets

The Alphabet-backed immunotherapy developer secured nearly $588m in what was reputedly the largest ever flotation for a preclinical life sciences company.

Feb 5, 2021
© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here